Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug
Most of the money raised will come from the SPAC itself, with approximately $75m to be raised through a private round with backers including Foresite, RA Capital Management, Frazier Life Sciences
Latest news
-
Sanofi pays $160m upfront to acquire Tidal Therapeutics
It received seed funding from Mission BioCapital, which was joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures and
-
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
Xeljanz is approved in the US for use in adults with rheumatoid arthritis (RA) who have not responded well to methotrexate treatment. ... When the FDA first approved Xeljanz, it required Pfizer to complete a safety clinical trial in RA patients to
-
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
In phase 3 trials, Jyseleca was shown to be effective in reducing the symptoms of RA, including joint tenderness and swelling. ... FINCH 3 compared Jyseleca alone or in combination with methotrexate as a front-line therapy for patients with
-
The best work in healthcare communications shines at virtual Communiqué Awards
3.Excellence in Global Education Meetings/Stand-Alone Events. Sponsored by HEALTH UNLIMITED. Winner: LiBRA 2019: Looking Beyond the Joint in Rheumatoid Arthritis (RA): Is There a Missing Link in RA
-
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... ICER also presented concerns over the long-term impact of
Sanofi pays $160m upfront to acquire Tidal Therapeutics
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
The best work in healthcare communications shines at virtual Communiqué Awards
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
More from news
Approximately 9 fully matching, plus 155 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Similar retrospective positive findings were recently published for the anti-diabetic, glucagon-like peptide-1 receptor agonist (GLP1-RA), which was also found to reduce neuroinflammation.
-
Setting up for success in a post-Brexit, post-pandemic Britain
and Rheumatoid Arthritis (RA). ... More than 400, 000 people in the UK live with RA (around 380, 000 in England), and it is recognised as a condition that can cause debilitating physical pain, affect mental
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
Alzheimer’s: the search for a cure
Setting up for success in a post-Brexit, post-pandemic Britain
Drug launches to watch in 2019
European CTR implementation advances ethical assessment of clinical trials
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
RA Consultants Private Limited
RA Consultants Private Limited.
-
The other side of … rheumatoid arthritis
So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed.
-
Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards
LiBRA is a multichannel program, focused on inspiring and enabling clinical behavior change to achieve better disease control for patients with RA. ... Lisa Druce, Managing Director, Lighthouse Medical Communications US, commented “RA is a chronic
-
Lucid Group scoop a win and a high commendation at Communiqué 2020
Its programme – ‘LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?’ – won the category, with a high commendation going to ‘CLEAR HORIZONS –
-
Lucid Group are shortlisted in three categories for Communiqué 2020
LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?
More from PMHub
Approximately 2 fully matching, plus 29 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Sanofi to buy mRNA tech partner, Translate Bio, for $3.2bn
- Novartis to proceed with phase 3 trial for intrathecal OAV-101 in older SMA patients
- Ask the writers: Transitioning from academia to medical writing
- Amanda Pritchard becomes NHS England’s first female chief executive
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
- A market-adapted agile approach to launch excellence
- Communicating for change – creating effective medical communications
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
